Beijing, China, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (NASDAQ: PTHL) (the “Company”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today announced, on October 20, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that based on the closing bid price of the Class A ordinary shares of the Company for the last 30 cons ...

Core Viewpoint - Pheton Holdings Ltd has issued a statement addressing recent market volatility and a speculative article that has negatively impacted its share price, denying any involvement in stock price manipulation or acquisition rumors [2][3]. Company Response - The management team of Pheton categorically denies any knowledge or participation in rumors regarding an acquisition by Gilead Sciences, asserting that such claims are false [3]. - Pheton plans to engage with market makers, Nasdaq, and regulatory bodies to hold responsible parties accountable for the misinformation [4]. Shareholder Protection - The company acknowledges the concerns raised among investors and is enhancing internal controls and communications to counter misinformation effectively [5]. Commitment to Governance - Pheton emphasizes its commitment to corporate governance, transparency, and accountability, focusing on long-term shareholder value through strategic growth opportunities [6]. Business Foundation - Pheton is built on trust, innovation, and value creation, expressing confidence in its underlying business strength and long-term strategy [7]. Communication with Shareholders - The company values shareholder trust and commits to providing accurate and timely disclosures to the investor community [8]. Company Overview - Founded in 1998, Pheton Holdings Ltd specializes in healthcare solutions for brachytherapy, with its lead product being a Treatment Planning System that enhances the safety and effectiveness of cancer treatment [9].